The 10-year data from the PRIME II trial suggest that radiotherapy after breast-conserving surgery can be omitted for women aged 65 years or older with low-risk, hormone receptor-positive early breast cancer.

The phase 1 RadioPARP trial points to the tolerability of administering olaparib concomitantly with adjuvant radiotherapy in patients with early-stage triple-negative breast cancer and residual disease after neoadjuvant chemotherapy.

Long-term postoperative androgen deprivation therapy may improve metastasis-free survival versus short-term therapy in men receiving radiotherapy after radical prostatectomy for prostate cancer, research suggests.

Men who receive radiotherapy for localized prostate cancer have a significantly elevated risk for a second primary cancer relative to their counterparts not exposed to radiotherapy, suggests a database analysis.

Radiotherapy may not be necessary for patients with the luminal A breast cancer intrinsic subtype and a low clinical risk for recurrence, report the LUMINA investigators.

Individuals with non-small-cell lung cancer and brain metastases may benefit from treatment with immune checkpoint inhibitors plus radiotherapy after neurosurgical resection, findings indicate.

Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.

Adding low-dose or hypofractionated radiotherapy to durvalumab plus tremelimumab offers no significant benefit to people with non-small-cell lung cancer that is resistant to PD-1 or PD-L1 inhibition, US study findings indicate.

Black men with localized prostate cancer fare better than their White counterparts after definitive radiotherapy, suggests a meta-analysis.

Definitive radiotherapy without systemic therapy may be a feasible strategy for the treatment of oligometastatic renal cell carcinoma, phase 2 study findings indicate.

Study findings suggest that using a genomic-adjusted radiation dose may help overcome the heterogeneity of tumor response to radiotherapy and improve overall survival for patients with cancer.

Researchers have found no significant difference in the tolerability of the Moderna SARS-CoV-2 vaccine among cancer patients who received radiotherapy in the 6 months prior to vaccination and cancer-free controls.

Postprostatectomy salvage radiotherapy guided by 18 F-fluciclovine-PET–CT is associated with improved outcomes relative to that guided by conventional imaging, research suggests.

High-dose, twice-daily thoracic radiotherapy may improve survival among patients with limited-stage small-cell lung cancer, phase 2 study findings indicate.

The number and location of bone metastases, as determined by conventional imaging, are associated with the survival benefit of prostate radiotherapy in men with newly diagnosed metastatic prostate cancer, STAMPEDE trial data show.

The total number of radiotherapy courses delivered in England fell significantly during the first peak of the COVID-19 pandemic but this was accompanied by a rapid increase in the use of hypofractionated regimens, study data show.

Dose intensification does not improve the outcomes of salvage radiotherapy after radical prostatectomy, the SAKK 09/10 investigators have reported at the 2021 Genitourinary Cancers Symposium.

Patients with intermediate-to-high-risk localized prostate cancer report similar long-term bowel and urinary symptoms and sexual function whether treated with ultra-hypofractionated radiotherapy or conventional radiotherapy, phase 3 study data show.

Physicians and patients differ in their assessment of side effects following radiotherapy for breast cancer, researchers have found.

Data from the phase 3 RADICALS-RT, RAVES, and GETUG-AFU 17 trials and the ARTISTIC meta-analysis suggest that observation with early salvage radiotherapy should be the standard of care for men undergoing radical prostatectomy for localized or locally advanced prostate cancer.